Skip to Content
  • Revenues ($M)
    $6,149
  • Revenue Percent Change
    -
  • Profits ($M)
    $956
  • Profits Percent Change
    -
  • Assets ($M)
    $12,329
  • Employees
    17,000
  • Market Value — as of March 31, 2016 ($M)
    $27,522
  • Previous Rank
    -
  • Morning Consult Brand Index
    D-

Baxalta, a biopharmeceutical company that specializes in treating rare conditions, was spun off from the healthcare giant Baxter International (ranked No. 286 on this year’s Forutne 500) last July. Earning $6.1 billion in revenue its inaugural year, the young company is looking forward to greater growth as it awaits the conclusion of a $32 billion merger with Shire.

41319CFF-E47E-4BA5-B1B8-ECA4D480B0DFCreated with sketchtool.62900797-6A09-46DF-8323-A45758A81292Created with sketchtool.Looking for leads, investment insights, or competitive intelligence?Buy Now

Company Info

CEO
Ludwig N. Hantson
Sector
Health Care
Industry
Pharmaceuticals
HQ Location
Bannockburn, IL
Websitehttp://www.baxalta.com
Years on Fortune 500 List1
Employees17,000
Spun off from Baxter International (2015 rank: 286), July 1, 2015. Acquired by Shire (Ireland), June 3, 2016.

Key Financials (last fiscal year)

$ millions% change
Revenues ($M)$6,149-
Profits ($M)$956-
Assets ($M)$12,329-
Total Stockholder Equity ($M)$3,924-
Market Value — as of March 31, 2016 ($M)$27,522-

Profit Ratios

Profit as % of Revenues15.5%
Profits as % of Assets7.8%
Profits as % of Stockholder Equity24.4%

Earnings Per Share (Last Fiscal Year)

Earnings Per Share ($)1.4
EPS % Change (from 2014)-
EPS % Change (5 year annual rate)-
EPS % Change (10 year annual rate)-

Total Return

Total Return to Investors (2015)-
Total Return to Investors (5 year, annualized)-
Total Return to Investors (10 year, annualized)-